TLR agonizts have been approved by the Food and Drug Administration for cancer and cancer-related conditions such as Bacillus Calmette–Guérin (BCG) that targets both TLR4 and TLR2 for the treatment of superficial transitional bladder cell carcinoma; monophosphoryl lipid A as adjuvant to Cervarix® for the prophylaxis of HPV-associated cervical cancer, and Imiquimod targets TLR7 for treating basal cell carcinoma and actinic keratosis [49]. This evidence concerns the gene TLR4 and actinic keratosis.